HERZLIYA, IsraelFeb. 6, 2020 /PRNewswire/ — NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow or halt ALS progression, announced today the initiation of two clinical studies to evaluate the benefit of PrimeC for ALS patients. A Phase IIa study is being conducted in Israel at Tel-Aviv Sourasky Medical Center (TASMC), by Prof. Vivian Drory. A similar study is being conducted in the USA at two sites: BNI (The Barrow Neurological Institute) in Phoenix Arizona, by Prof. Jeremy Shefner and Columbia University in NYC, by Dr. Jinsy Andrews. The studies plan to enroll 45 patients, 15 at each site. In addition to safety and tolerability, the company will evaluate the drug’s efficacy and ability to slow disease progression and to improve quality of life.

PrimeC targets two fundamental mechanisms underlying the pathogenesis of ALS. The two clinical studies were initiated following exceptional results PrimeC achieved in pre-clinical models of ALS. In these studies, conducted on two different zebra-fish models, each with a different ALS-causing mutation, the transgenic fish were treated either with PrimeC or left untreated. The swimming abilities of the PrimeC treated ALS fish increased drastically compared to the controls, and significantly more than with any other compound previously tested in these models. Furthermore, the analysis of motor neurons, neuromuscular junctions and aspects of the immune system in the ALS treated fish, indicated that PrimeC is neuroprotective.

More: https://finance.yahoo.com/news/neurosense-therapeutics-receives-orphan-drug-140000174.html

Editorial Team
Author: Editorial Team